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No other protein shows such multiplicity and diversity 
of functions as the tumor suppressor p53 [1,2]. Initially, 
the role of p53 as “the guardian of the cellular genome” 
was considered to be providing protection from 
progression to malignancy. This was mediated by its 
function as a transcription factor of the genes 
controlling cell cycle and apoptosis [3]. Subsequent 
studies have identified a large variety of diverse genes 
regulated by p53. Among them are the genes 
modulating cellular senescence, DNA repair, oxidative 
stress, longevity, angiogenesis, differentiation, 
glycolysis, tumor motility and invasion, and even bone 
remodeling [1,2]. Independently of its transcription-
regulatory mechanism p53 can also directly interact 
with proteins of Bcl2 family controlling the execution 
of apoptotic response [4]. 
 
It was recently reported that induction of cell 
senescence by ectopic expression of p21 and 
doxorubicin when combined with upregulation of p53 
by inhibition of Mdm2, mediated by nutlin-3a, led to 
cell quiescence. The quiescence was reversible: upon 
removal of nutlin-3a the cells reentered the cell cycle 
[5]. This observation prompted the authors to postulate 
the use of Mdm2 antagonists in conjunction with 
chemotherapy to reversibly arrest normal cells, thereby 
protecting them from the drugs targeting cell cycle 
progression (cyclotherapy) [5]. Consistent with this 
observation were findings that p53 plays an important 
role in regulating stem cell quiescence, self-renewal and 
aging [6].  
 
What is the mechanism by which p53 converts the cell 
response to the ectopic expression of p21 (cell cycle 
arrest) from senescence to quiescence?  In recent studies  
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Demidenko et al., addressed this question and in elegant 
experiments the authors demonstrated the “paradoxical” 
capabilities of p53, one to suppress cell senescence by 
inducing quiescence and another, already known, to 
induce senescence [7]. Suppression of senescence 
paralleled by induction of quiescence by p53 required 
its transactivation function, and in analogy to 
rapamycin, was mediated, at least in part, by inhibition 
of mTOR pathway [8]. Further evidence on the 
involvement of mTOR pathway in the direction the cell 
undertakes to become either senescent or quiescent is 
provided in the article in the current issue of Aging [9] 
consistent with their prior findings, the authors in this 
article report that induction of cell cycle arrest in the 
WI-38-tert or HT-1080-p21 cells, in which nutlin-3a 
inhibited mTOR, led to quiescence rather than 
senescence. In contrast, augmentation of mTOR 
pathway led to induction of senescence [9]. The data 
collectively suggest that in the process of induction of 
cells senescence or quiescence the primary role of p53 
is in arresting cells in the cell cycle. However, the 
ongoing cell growth (rRNA synthesis) in the arrested 
cells mediated by mTOR pathway is the deciding factor 
as to whether they undergo senescence (mTOR 
activation) or quiescence (mTOR inhibition). The factor 
responsible for the apparent “paradoxical” properties of 
p53 was the dual and separate function of this protein, 
one arresting cells in cell cycle and another, inhibiting 
mTOR [7].   
 
Senescent cells are characterized by large cell/nuclear 
size and “flattened” morphology, a characteristic feature 
of growth imbalance. It was shown before that cellular 
content of RNA (of which 95% is rRNA) in cycling 
cells is > 10-fold higher than in quiescent cells [10]. In 
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the senescent phenotype is paralleled by several-fold 
rise in rRNA abundance [11]. It is also known that 
mTOR pathway regulates the synthesis of ribosomal 
components including the transcription and processing 
of pre-rRNA, expression of ribosomal proteins and the 
synthesis of 5SRNA [12]. The critical role of mTOR is 
thus in adjusting the ribosome biogenesis and overall 
protein biosynthetic capacity (cell growth) to the 
signaling through the growth factors pathway and 
coordinating it with the rate of cell cycle progression. 
Within this context cell senescence can be characterized 
as the uncoupling of the rate of cell cycle progression 
and cell growth mediated by mTOR. Of interest is the 
observation that mTOR activity is accelerated in 
hematopoietic stem cells from old mice compared to 
young mice prompting the authors to suggest that 
mTOR inhibitors can be used to rejuvenate aging 
hematopoietic cells [13].   
 
Not disregarded should be a possibility of regulation of 
cell senescence by p53 via induction of autophagy. Here 
again the diverse “paradoxical” properties of p53 have 
been observed, namely the induction of autophagy upon 
activation and expression of this protein above the basal 
level and inhibition of autophagy after its induction to 
the basal level [14]. This “paradoxical” effect of p53, 
which on the surface appears to be contradictory, was 
metaphorically compared with the two-faced Roman 
mythology God and named The “Janus of Autophagy” 
[15]. Considering how extensively intertwined are the 
pathways of autophagy, senescence, apoptosis and 
aging the elucidation of the mechanisms involved in the 
induction of senescence versus quiescence by p53 is 
additionally complicated. Inhibition of mTOR while it 
enhances autophagy and thus is expected to delay 
senescence may also be lethal to cancer cells [16].   
Further studies are needed to resolve how the “Janus of 
Autophagy relates to the “Janus of Cell Senescence” or 
to the “Janus of Cell Quiescence”. 
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